Lyndra Therapeutics

Lyndra Therapeutics Pioneers the First Oral, Ultra-Long-Acting, Extended-Release Therapy, Which Has the Potential to Radically Transform How People Take Medications by Allowing Patients to Take a Pill Once a Week Instead of Once a Day. The Company’s Breakthrough Extended-Release Oral Capsule is Designed to Deliver Consistent Drug Levels Over a Week or Up to a Month from a Single, Normally Sized Capsule—Something Never Before Achieved in Oral Therapies. Lyndra's Robust Pipeline Comprises Therapies with Established and Well-Known Safety Profiles Across Many Disease Areas Where Non-Adherence Is a Significant Driver of Outcomes, Including Schizophrenia and Other Central Nervous System Disorders, Diabetes, Cardiovascular Diseases, and Opioid Use Disorder, Among Others. The Company is Also Committed to Advancing Its Platform Through Partnerships, Such as with the Bill & Melinda Gates Foundation, and via NIH Funding, in New Chemical Entities and Various Crucial Global and Public Health Opportunities.